Market Share in Infectious Disease Molecular Testing

Download Market Share in Infectious Disease Molecular Testing

Post on 14-Apr-2017

22 views

Category:

Healthcare

8 download

Embed Size (px)

TRANSCRIPT

<ul><li><p> Market Share in </p><p>Infectious Disease </p><p>Molecular Testing Infectious disease is a key area to watch in molecular, though </p><p>it has many applications. This brief White Paper reviews the </p><p>market share picture for molecular testing. It is based on </p><p>Kalorama Informations 7th</p><p> Edition of its World Market for </p><p>Molecular Diagnostics report. </p><p>There is little gray area in terms of undetermined market share </p><p>in molecular infectious disease diagnostics. Eight companies are </p><p>estimated to account for 86% of the global market (Figure </p><p>accompanying). Roche Diagnostics has been an unmovable </p><p>leader with a market share estimated at 21%. The companys </p><p>resources and history in the market have allowed it to adapt and diversify as needed, most </p><p>recently with its Liat system for CLIA-waived molecular infectious disease testing, HPV assay </p><p>FDA-approved for primary screening, and new viral load assays for its cobas 6800/8800 core lab </p><p>virology systems. Hologic claims a large market share through its leadership in the molecular </p><p>CT/NG and HPV testing space. Cepheid and bioMrieux have significantly increased market </p><p>share in molecular infectious disease diagnostics over the past few years through respective </p><p>placements of GeneXpert and FilmArray systems in hospital labs. The success of Cepheid and </p><p>bioMrieux validates the development efforts of competitors in </p><p>the same space of decentralized molecular testing. Remaining market leaders Becton, </p><p>Dickinson &amp; Co. (BD), Abbott Diagnostics, Siemens Healthcare Diagnostics have been </p><p>markedly less dynamic in molecular infectious disease testing, though BD has been active in </p><p>more fully addressing its markets in HAI and womens health/sexual health. Abbott and Siemens </p><p>have stuck more to core molecular infectious disease markets in virology (HIV/hepatitis). </p></li><li><p>Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care </p><p>that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, </p><p>patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test </p><p>kits, other reagents and instruments that are used for clinical testing in settings that include </p><p>reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-</p><p>patient testing sites such as clinics and physician offices. </p><p>The primary technologies for clinical molecular diagnostics include nucleic acid amplification </p><p>tests (NAATs) based on real-time PCR (qPCR) and other amplification-detection protocols; </p><p>direct nucleic acid probe tests such as in situ hybridization (ISH) and its fluorescent ISH (FISH); </p><p>next-generation sequencing (NGS); amplification followed by probe-based hybridization on </p><p>arrays (or microarrays); and other related methods. </p><p>The market for infectious disease diagnostics was traditionally dominated by virology or HIV </p><p>and hepatitis testing including infection diagnosis, virus genotyping, and viral load testing. </p><p>Together, HIV and hepatitis still represent roughly 40% of the entire molecular diagnostics </p><p>market in infectious diseases. Hospital-acquired infections and bloodstream infections now </p><p>represent the largest market segment due to the threat of antimicrobial resistance (AMR) in </p><p>hospitals and rising complexity of testing deployed in cases of inpatient infections. Molecular </p><p>assays have been highly successful in hospital markets due to their unique ability to identify the </p><p>infection and characterize resistance within actionable timelines. </p></li><li><p> N O W P U B L I S H E D </p><p>The World Market for Molecular Diagnostics 7th Edition </p><p>http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/ </p><p>Molecular tests have become routine and expanded to all levels of healthcare from the </p><p>pathology lab all the way to the doctors office and clinics of </p><p>the developing world. Molecular diagnostics now represents </p><p>more than one-tenth of the global IVD market with a growth </p><p>trajectory secured through platform innovation in lower-cost </p><p>nucleic acid amplification tests (NAATs) and clinical next-</p><p>generation sequencing (NGS). </p><p>Kalorama Information has now published its 7th</p><p> edition of The </p><p>World Market for Molecular Diagnostics. This </p><p>comprehensive report provides detailed information on </p><p>relevant test kits, other reagents and instruments that are used for clinical testing. Market data is </p><p>provided, products on the market detailed and trends discussed. While not matching its </p><p>explosive market growth in years past, clinical molecular diagnostics has delivered on its </p><p>promise in health care. Kalorama Information analyst Emil Salazar details the status of the </p><p>molecular diagnostics market, as it stands in 2017. </p><p>The major applications of clinical molecular </p><p>diagnostics include the following, and are covered in </p><p>the report: </p><p> Infectious disease diagnostics - molecular </p><p>microbiology and virology, including the detection, </p><p>identification, quantification and nucleic-acid based </p><p>resistance or susceptibility profiling of pathogens. </p><p> Blood transfusion diagnostics - nucleic acid </p><p>screening (NAT) of donated blood, often pooled </p><p>samples, for the detection of active infections </p><p>responsible for transfusion transmitted infections </p><p>Molecular diagnostics is </p><p>demonstrating revenue growth </p><p>at more than twice the rest of </p><p>the IVD market While not </p><p>matching its explosive market </p><p>growth in years past, clinical </p><p>molecular diagnostics has </p><p>delivered on its promise in </p><p>healthcare -Emil Salazar, IVD Analyst and </p><p>Author </p><p> Detailed Market Intelligence in All Segments of Molecular Testing - Based on Real Company Events and Intelligence </p><p>http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/</p></li><li><p> Histology / cytology diagnostics - largely synonymous with in situ hybridization (ISH) </p><p>methods that use direct hybridization of chromogenic (CISH) or fluorescent (FISH) </p><p>nucleic acid probes within slided tissue or suspended cell samples viewed under </p><p>microscopy. </p><p> Cancer diagnostics - tissue, blood and urine samples can be assayed using nucleic acid </p><p>amplification tests (NAATs) or sequencing to diagnose, prognose and identify key </p><p>mutations for targeted therapies; future additional capabilities are premised on liquid </p><p>biopsy sampling (non-invasive fluid samples such as venous blood or urine) and next-</p><p>generation sequencing (NGS). </p><p> Transplant diagnostics - various PCR-based </p><p>methodologies, Sanger sequencing and NGS used to type </p><p>HLA alleles in low to high resolution in order to match </p><p>donors and recipients. </p><p> Inherited disease diagnostics - diagnosis of rare genetic </p><p>diseases and other inherited traits. </p><p>Once esoteric, molecular tests have become routine and </p><p>expanded to all levels of healthcare from the pathology lab all </p><p>the way to the doctors office and clinics of the developing </p><p>world. Kalorama Information analyst Emil Salazar details the </p><p>status of the molecular diagnostics market, as it stands in 2017. </p><p>Detailed Market Analysis </p><p>As part of its coverage, the following is included:: </p><p> Molecular Diagnostics for Infectious Disease Market, 2016-2021 </p><p> Molecular Diagnostics for Cancer Market 2016-2021 </p><p> Molecular Diagnostics for NAT Blood Screening Market 2016-2012 </p><p> Molecular Diagnostics for Hepatitis Market </p><p> HIV Molecular Diagnostics Market, 2016 to 2021 </p><p> HAIs/Sepsis Molecular Diagnostics Market, 2016 to 2021 </p><p> CT/NG Molecular Diagnostics Market, 2016 to 2021 </p><p> HPV Molecular Diagnostics Market, 2016 to 2021 </p><p> Respiratory Molecular Diagnostics Market, 2016 to 2021 </p><p> Mycobacteria/TB Molecular Diagnostics Market, 2016 to 2021 </p><p> Other Infectious Disease Molecular Diagnostics Market, 2016 to 2021 </p><p> in situ hybridization (ISH) Market by Application (Genetic Disorders, Cancer, </p><p>Infectious and Other) 2016 to 2021 </p><p> Other Histology Molecular Diagnostics Market, 2016 to 2021 </p><p> Inherited Diseases Molecular Diagnostics Market, 2016 to 2021 </p><p> Transplant Diagnostics Molecular Diagnostics Market, 2016 to 2021 </p><p>Kaloramas Report Contains Superior Graphics Designed to Clearly Explain Changes in the Market </p></li><li><p>Market Share and Global Segmentation </p><p>There are a great number of companies participating in these segments of molecular diagnostics, </p><p>from molecular specialists to the top-tier IVD companies. This report offers superior detail, </p><p>identifying market share not only for the overall molecular diagnostics market but for molecular </p><p>test categories, including: </p><p> Molecular Blood Testing Market Share Analysis </p><p> Molecular Cancer Testing Market Share Analysis </p><p> Molecular Transplantation Market Share Analysis </p><p> Molecular Infectious Disease Market Share Analysis </p><p> Inherited Disease Testing Market Share Analysis </p><p>The segmented market share allows competitors and interested market-watchers to see not only </p><p>how a company is performing in the overall molecular diagnostics market, but also in their </p><p>specialty area. </p><p>To assist in global business planning efforts, this report contains market estimates for major </p><p>world regions including the United States, Europe, Japan, China and Latin America. Data in the </p><p>report includes: </p><p> Regional Markets for Molecular Blood Screening Geographic Market Segmentation </p><p>( United States, Europe, Japan, China, Latin America, Rest of World) </p><p> Regional Markets for Molecular Cancer Testing Market Share ( United States, </p><p>Europe, Japan, China, Latin America, Rest of World) </p><p> Regional Markets for Molecular Transplantation Market Share ( United States, </p><p>Europe, Japan, China, Latin America, Rest of World) </p><p> Regional Markets for Molecular Infectious Disease Market Share ( United States, </p><p>Europe, Japan, China, Latin America, Rest of World) </p><p> Regional Markets for Inherited Disease Testing Market Share ( United States, </p><p>Europe, Japan, China, Latin America, Rest of World) </p></li><li><p>Superior Company Profiling </p><p>This report contains profiles of major companies competing in molecular diagnostics. For each </p><p>company, revenues, market share, products on the market and acquisitions and other deals are </p><p>detailed. The following companies are profiled in the report: </p><p> Abbott Diagnostics </p><p> Advanced Cell Diagnostics </p><p> Affymetrix (Thermo Fisher Scientific) </p><p> Agilent Technologies </p><p> Alere </p><p> Amoy Diagnostics </p><p> Applied Spectral Imaging </p><p> Beckman Coulter (Danaher) </p><p> Becton, Dickinson &amp; Co. (BD) </p><p> Beijing Genomics Institute (BGI) </p><p> Berry Genomics </p><p> Biocartis </p><p> bioMrieux </p><p> Bio-Rad Laboratories </p><p> Cepheid (Danaher) </p><p> Covaris </p><p> Dako (Agilent Technologies) </p><p> Eiken Chemical </p><p> Epigenomics </p><p> Exosome Diagnostics </p><p> Genmark Diagnostics </p><p> Grifols </p><p> Immucor </p><p> Janssen Diagnostics (Johnson &amp; Johnson) </p><p> Leica Biosystems (Danaher) </p><p> Luminex Corporation </p><p> Meridian Bioscience </p><p> Nanosphere (Luminex) </p><p> Nanostring Technologies </p><p> Qiagen </p><p> Quidel </p><p> Roche Diagnostics </p><p> Siemens Healthcare Diagnostics </p><p> Thermo Fisher Scientific </p><p> Others </p><p>FOR MORE INFORMATION, OR TO ORDER: </p><p>http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/ </p><p>http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/</p></li></ul>

Recommended

View more >